Mitofusin 1 (Mfn1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitofusin 1 (MFN1) is a dynamin-like GTPase essential for mitochondrial outer membrane fusion. It is encoded by the MFN1 gene located on chromosome 3q26.33 and plays a critical role in maintaining mitochondrial morphology and function.
| Mitofusin 1 | |
|---|---|
| Gene Symbol | MFN1 |
| Full Name | Mitofusin 1 |
| Chromosome | 3q26.33 |
| NCBI Gene ID | 55626 |
| OMIM | 607616 |
| Ensembl ID | ENSG00000106609 |
| UniProt ID | Q9UQF0 |
MFN1 is a dynamin-related GTPase with the following domains:
MFN1 mediates mitochondrial outer membrane fusion in three steps[1]:
MFN1 works together with MFN2 (Mitofusin 2) and OPA1 (inner membrane fusion) to complete mitochondrial network fusion.
In AD, MFN1 dysfunction contributes to:
MFN1 plays important roles in PD:
MFN2 mutations cause CMT2A (type 2A axonal neuropathy), but MFN1 is also implicated in peripheral neuropathy pathogenesis.
| Approach | Mechanism | Status |
|---|---|---|
| Small molecule MFN activators | Promote mitochondrial fusion | Research |
| Gene therapy | AAV-MFN1 delivery | Preclinical |
| Mitochondrial antioxidants | Reduce oxidative stress | Research |
| Disease | Role | Evidence |
|---|---|---|
| Alzheimer's Disease | Mitochondrial fragmentation | Altered MFN1 in AD brain[2] |
| Parkinson's Disease | Mitophagy impairment | MFN1 dysfunction in PD[3] |
| Charcot-Marie-Tooth | Peripheral neuropathy | MFN1/2 mutations |
| ALS | Mitochondrial dysfunction | Altered fusion in ALS |
MFN1 is widely expressed in neurons:
[1] Cao YL, et al. MFN1 structures reveal nucleotide-triggered dimerization. Cell. 2017.
[2] Wang X, et al. Mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis. 2008.
[3] Poole AC, et al. The PINK1/Parkin pathway regulates mitochondrial dynamics. Proc Natl Acad Sci USA. 2008.
The study of Mitofusin 1 (Mfn1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cao YL, et al. MFN1 structures reveal nucleotide-triggered dimerization. Cell. 2017;168(5):816-828.e15.
[2] Wang X, et al. Mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis. 2008;14(4):441-449.
[3] Poole AC, et al. The PINK1/Parkin pathway regulates mitochondrial dynamics. Proc Natl Acad Sci USA. 2008;105(42):16322-16327.